35582 membres inscrits Accès abonné revues  Aide   Newsletter    Me connecter
Les Communiqués
 
 
     Nasdaq OMX
 
Rechercher dans le flux Nasdaq GlobeNewswire
Rechercher
Bavarian Nordic Announces Presentation of Phase 1 Data for its RSV Vaccine at International RSV Symposium
Thu, 29 09 2016 13:00:14
COPENHAGEN, Denmark, September 29, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the presentation of data from a Phase 1 study of its novel, broad spectrum RSV (respiratory syncytial virus) vaccine candidate, MVA-BN RSV (...)
Bionor Pharma ASA : Primary inside Notification - Additional information
Thu, 29 09 2016 09:56:18
Bionor Pharma ASA STOCK EXCHANGE ANNOUNCEMENT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES Primary insider notification - additional (...)
Medigene AG: bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy
Thu, 29 09 2016 06:11:00
T cell receptor (TCR) therapeutic candidates against four targets to be generated using Medigene's proprietary TCR technology platform and bluebird bio's lentiviral vector, genome editing, synthetic biology, and manufacturing (...)
Ad hoc: bluebird bio and Medigene establish strategic T cell receptor (TCR) alliance in cancer immunotherapy
Thu, 29 09 2016 06:10:38
Disclosure of an inside information according to Article 17 MAR Martinsried/Munich and Cambridge, MA, 29 September 2016. Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, and bluebird bio, Inc. (Nasdaq: BLUE), USA, today (...)
Novo Nordisk announces plans to reduce workforce by approximately 1,000 employees
Thu, 29 09 2016 06:00:03
Bagsværd, Denmark, 29 September 2016 - Novo Nordisk has today announced its intention to reduce its workforce by approximately 1,000 employees of the 42,300 positions in the company's global organisation. This is one of several (...)
LivaNova PLC: Transaction in Own Shares
Thu, 29 09 2016 06:00:00
UK DISCLOSURE, Sept. 29, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (the " Company " or " LivaNova ") announces on 29 September 2016, the repurchase of 10,000 ordinary shares on 28 September 2016 as a part of the US (...)
MEDDAY PHARMACEUTICALS SA: Strengthens its Board with Two Senior Non-Executive Directors
Thu, 29 09 2016 06:00:00
MedDay Strengthens its Board with Two Senior Non-Executive Directors Paris, France, 28 September 2016 - MedDay, a biotechnology company focused on the treatment of nervous system disorders, is today pleased to (...)
Bionor Pharma ASA : Primary inside Notification - Jens Krøis
Thu, 29 09 2016 05:32:00
Bionor Pharma ASA STOCK EXCHANGE ANNOUNCEMENT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES Primary insider notification - Jens Krøis (...)
Bionor Pharma ASA : Primary inside Notification - Per S. Thoresen
Thu, 29 09 2016 05:31:00
Bionor Pharma ASA STOCK EXCHANGE ANNOUNCEMENT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES Primary insider notification - Per S. Thoresen (...)
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
Thu, 29 09 2016 05:30:00
Ongoing Phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis Favorable safety results shown in healthy volunteers receiving single ascending doses (SAD) in the study to date (...)
Deinove : 2016 interim results: Stability of net loss Strategic refocusing on carotenoids and antibiotics
Thu, 29 09 2016 05:30:00
2016 interim results: Stability of net loss Strategic refocusing on carotenoids and antibiotics Cash position: +?10.4 M at June 30, 2016 compared to +?12.4 M at December 31, 2015 Stability of (...)
Bionor Pharma - Expiry of subscription period and last day of trading in subscription rights today
Thu, 29 09 2016 05:30:00
BIONOR PHARMA ASA   STOCK EXCHANGE ANNOUNCEMENT   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES   Bionor Pharma - Expiry of (...)
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
Thu, 29 09 2016 05:30:00
Ongoing phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis Favorable safety results shown in healthy volunteers receiving single ascending doses (SAD) in the study to date MOR106 first (...)
Actelion to investigate all-oral combination therapy for patients with relapsing multiple sclerosis
Thu, 29 09 2016 05:00:00
ALLSCHWIL/BASEL, SWITZERLAND - 29 September 2016 - Actelion Ltd (SIX: ATLN) announced today that it will investigate the use of combination therapy with ponesimod and dimethyl fumarate (Tecfidera ® ) for patients with relapsing multiple (...)
ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP
Thu, 29 09 2016 05:00:00
Additional data from post-hoc analyses of the Phase II TITAN study to be presented at the European Congress on Thrombosis and Haemostasis (ECTH) GHENT, Belgium, 29 September 2016 - Ablynx [Euronext Brussels: ABLX; OTC: (...)
Poursuite de l'essai EffiKIR sans modification après la septième évaluation du comité de revue des données et de la tolérance
Thu, 29 09 2016 05:00:00
poursuite de l'essai EffiKIR sans modification aprÈs la SEPTIÈME Évaluation du comitÉ de revue des donnÉes et de la tolÉrance         Marseille, le 29 septembre 2016 Innate Pharma SA (Euronext Paris: (...)
Seventh data and Safety Monitoring Board Meeting of the EffiKIR trial recommends continuation without modification
Thu, 29 09 2016 05:00:00
SEVENTH DATA AND SAFETY MONITORING BOARD meeting of the EffiKir trial RECOMMENDs continuation without modification Marseille, France, September 29, 2016 Innate Pharma SA (the "Company" - Euronext Paris: (...)
Apricus Biosciences Closes $3.7 Million Registered Direct Offering
Wed, 28 09 2016 23:00:00
SAN DIEGO, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has closed a registered direct offering of shares (...)
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
Wed, 28 09 2016 20:30:00
ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo   (...)
Medtronic Receives FDA Approval for World's First Hybrid Closed Loop System for People with Type 1 Diabetes
Wed, 28 09 2016 17:19:01
The MiniMed ® 670G System Features the Company's Most Advanced SmartGuard(TM) Algorithm To-Date DUBLIN - Sept. 28, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it (...)
Présentation des données de tolérance des essais de phase I de Lirilumab en combinaison avec Nivolumab ou Ipilimumab au congrès de l'ESMO 2016
Wed, 28 09 2016 16:00:00
PrÉsentation Des donnÉes de tolÉrance des essais de Phase I de LIRILUMAB EN combinaison avec NIVOLUMAB ou IPILIMUMAB au congrÈs de l'ESMO 2016 Marseille, le 28 septembre 2016 Innate Pharma SA (Euronext Paris : (...)
Safety data for Lirilumab in combination with Nivolumab or Ipilimumab to be presented at the ESMO 2016 Congress
Wed, 28 09 2016 16:00:00
SAFETY DATA FOR LIRILUMAB IN COMBINATION WITH NIVOLUMAB OR IPILIMUMAB to be presented at the ESMO 2016 CONGRESS Marseille, September 28, 2016 Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) (...)
GLOBAL BIOENERGIES :First production of isobutene from wheat straw at the industrial pilot scale
Wed, 28 09 2016 15:36:48
First production of isobutene from wheat straw at the industrial pilot scale. Evry (France), and Planegg (Germany), 28 September 2016 - Global Bioenergies and Clariant are proud to announce today the first isobutene production (...)
GLOBAL BIOENERGIES : Première production d'isobutène à partir de paille à l'échelle du pilote industriel
Wed, 28 09 2016 15:36:48
Première production d'isobutène à partir de paille à l'échelle du pilote industriel Evry (France), et Planegg (Allemagne), le 28 Septembre 2016 - Global Bioenergies et Clariant annoncent aujourd'hui la première (...)
Bionor Pharma ASA - Mandatory notification of trade - Lars Høie
Wed, 28 09 2016 14:14:21
BIONOR PHARMA STOCK EXCHANGE ANNOUNCEMENT Lars Høie has on 28 September 2016 sold 25,000,000 shares, disposed of 1,500,000 Subscription Rights and exercised his remaining 96,199,303 Subscription Rights in the rights offering in Bionor Pharma ASA (...)
publicités
publicité
 
  KauriWeb

Afficher toutes les thématiques